SLBT (SL Science Holding) Other Stockholders Equity: $-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLBT SL Science Holding Ltd SLBT
12 GF Score
Price $3.29
! 3 Warning Signs
View Full Analysis

What is SL Science Holding Other Stockholders Equity?

SL Science Holding SLBT +24.39% 12 Other Stockholders Equity is $-0.00 Mil as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

SL Science Holding's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $-0.00 Mil.

SL Science Holding's quarterly Other Stockholders Equity stayed the same from Dec. 2024 ($0.00 Mil) to Jun. 2025 ($0.00 Mil) but then declined from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil).

SL Science Holding's annual Other Stockholders Equity declined from Dec. 2023 ($3.42 Mil) to Dec. 2024 ($0.00 Mil) and declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil).

SL Science Holding Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for SL Science Holding's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SL Science Holding Other Stockholders Equity Chart

SL Science Holding Annual Data
Trend Dec23 Dec24 Dec25
Other Stockholders Equity
3.42 0.00 -0.00

SL Science Holding Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity 3.42 0.00 0.00 0.00 -0.00
SLBT
12GF Score
SL Science Holding Ltd SLBT
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SL Science Holding Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
SL Science Holding (SLBT) has a Other Stockholders Equity of $-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on SL Science Holding and its competitors.
Is SL Science Holding's Other Stockholders Equity too high?
SL Science Holding's current Other Stockholders Equity is $-0.00 Mil. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Other Stockholders Equity compare to DMRA and BCAX?
SL Science Holding's Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on SL Science Holding and its competitors. SL Science Holding's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Other Stockholders Equity is $-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SL Science Holding Business Description

Address No. 479 Chongyang Road, 11th Floor, Nangang District, Taipei, TWN, 115010
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score

Get the complete analysis for SLBT

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price